News Bundle: 41 Hot Biotech Stocks to Watch

Biotech stocks failed to join a broad market rally on Friday with Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) losing the most after a Seeking Alpha article claimed a competing debate over whether hedge funds are bullish or bearish on the equity.

Zalicus Inc (NASDAQ:ZLCS) tumbled 5.9% on a sale of 113000 shares by the company’s CEO.
Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) lost 5.26%, facing a weekly fall of 6.09% to trim year-to-date rally to 2.86%.

Celsion Corporation (NASDAQ:CLSN) plunged 4.24%, extending decline after analysts at Brean Capital downgraded the stock to a “sell” from a “buy” rating.

Biosante Pharmaceuticals Inc (NASDAQ:BPAX) fell 3.08% while ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Sequenom, Inc. (NASDAQ:SQNM), Theravance Inc (NASDAQ:THRX) and Dendreon Corporation (NASDAQ NDN) each decreased less than 3%.

VIVUS, Inc. (NASDAQ:VVUS) extended fall a day after Brean Capital downgraded the VVUS stock to “Sell” from “Hold”.

Amgen, Inc. (NASDAQ:AMGN) was down on Friday. The world’s largest biotechnology firm has recently marked a key lobbying victory in the recent fiscal-cliff deal as has a section granting the company an additional two years to sell Sensipar without government controls.

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) declined about 1.5%, suffering third fall in a row after the company declared an underwritten public offering of 4,400,000 shares of its common stock.
Illumina, Inc. (NASDAQ:ILMN) edged down after San Diego-based company was seen as attractive takeover target.

InterMune, Inc. (NASDAQ:ITMN) dropped 0.50% after it priced Public Offerings.
NuPathe Inc (NASDAQ ATH) traded actively on Friday but was unable to extend rally it saw on Thursday after the U.S. Food and Drug Administration (FDA) approved Zecuity for the acute treatment of migraine.

More on the down side, MannKind Corporation (NASDAQ:MNKD), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Hemispherx BioPharma, Inc (NYSEAMEX:HEB), Peregrine Pharmaceuticals (NASDAQ PHM), Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) and PDL BioPharma Inc. (NASDAQ DLI) all ended in negative territory.

Despite hitting new high, YM BioSciences Inc. (USA) (NYSEAMEX:YMI) made no change by the of close on Friday.

Surprisingly there were 5 more stocks in the biotechnology industry including Inovio Pharmaceuticals, Inc. (NYSEAMEX:INO), Exelixis, Inc. (NASDAQ:EXEL), Galena Biopharma Inc (NASDAQ:GALE), Geron Corporation (NASDAQ:GERN) and Cell Therapeutics Inc (NASDAQ:CTIC) that ended the day at breakeven level.

On the positive side, Viropharma Inc (NASDAQ:VPHM) was among top gainers after a report that key product Cinryze (C1 esterase inhibitor [human]) was found useful in providing relief from the symptoms of hereditary angioedema (HAE) attacks in pediatric patients and also helped decrease the rate of attacks.
Medivation, Inc. (NASDAQ:MDVN) jumped 2.75%, trimming early decline to end the day at $54.94. On Monday, analysts at Zacks upgraded the MDVN stock from a “neutral” rating to an “outperform” rating.

Celgene Corporation (NASDAQ:CELG) hit all-time high after Forbes reported that Wall Street is optimistic about the company, which is scheduled to release its fourth quarter earnings on Thursday, January 24, 2013.

ImmunoGen, Inc. (NASDAQ:IMGN) rallied after the company unveiled a plan to host a conference call at 8:00 a.m. ET on Friday, January 25, 2013, to discuss its corporate results for the three-month period ended December 31, 2012, the second quarter of the Company’s 2013 fiscal year.
CEL-SCI Corporation (NYSEAMEX:CVM) successfully rebounded from a decline near record low while Seattle Genetics, Inc. (NASDAQ:SGEN) and Gilead Sciences, Inc. (NASDAQ:GILD) traded near 52-week high.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) marked its best since IPO after the company reported inducement grants under NASDAQ Listing Rule 5635(c)(4).

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) ended in green after a plan to present a corporate update at the upcoming Noble Financial Capital Markets’ Ninth Annual Equity Conference on Wednesday, January 23, 2013 at 9:30 a.m. EST to be held at the Hard Rock Hotel in Hollywood, FL.

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) and Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) both recorded gains of more than 1.2% while Nektar Therapeutics (NASDAQ:NKTR), Biogen Idec Inc. (NASDAQ:BIIB) and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) each added less than 1% in price.